Minimalistic Implant for Percutaneous Magnetic Hyperthermia-Based Combination Therapy of Hepatocellular Carcinoma

Percutaneous local thermal therapy, containing radio frequency and microwave ablation, is widely utilized in the clinical management of hepatocellular carcinoma (HCC) due to its minimal invasiveness and favorable therapeutic outcomes. However, its further development is limited by a prolonged ablation duration and the risk of excessive heating. Magnetic hyperthermia therapy (MHT) provides a new perspective for percutaneous tumor thermal ablation due to its superior tissue penetration capability and safety. Herein, an iron foam-agarose gel-drug (IF-Aga-drug) implant is prepared using a minimalistic method for percutaneous combination therapy of HCC. The excellent conductivity of IF endows it with strong heating capability owing to eddy current loss in an alternating magnetic field (AMF), while the abundant pores provide ample space for drug loading. Agarose gel imparts the IF platform with universal and efficient drug-loading capacity and controlled drug-release capability that is responsive to magnetic hyperthermia. Doxorubicin (DOX) is utilized as a representative drug to construct the IF-Aga-DOX implant, which is successfully employed in ultrasound-guided, magnetic hyperthermia-based combination chemotherapy for orthotopic HCC in rabbits under ultralow-power magnetic field intensities (Happl<middle dot>fappl = 2.25 x 108 A m-1 s-1). The developed IF-Aga-drug implant platform offers a convenient and versatile strategy for percutaneous tumor therapy.